Showing results (81-90 of 314) with videos related to

Sort By:
Pageof 32
International Journal of Cancer|January 9, 2001
Correlation of clinical data with proteomics profiles in 24 patients with B-cell chronic lymphocytic leukemiaT Voss, H Ahorn, P Haberl, et al.
Applied and Environmental Microbiology|May 29, 1999
Deletions in the gibberellin biosynthesis gene cluster of Gibberella fujikuroi by restriction enzyme-mediated integration and conventional transformation-mediated mutagenesisP Linnemannstöns, T Voss, P Hedden, et al.
Molecular Pharmacology|January 1, 1996
Thiophosphorylation of the G protein beta subunit in human platelet membranes: evidence against a direct phosphate transfer reaction to G alpha subunitsM Hohenegger, T Mitterauer, T Voss, et al.
Cancer Treatment Reports|April 1, 1979
A 10-year experience with topical mechlorethamine for mycosis fungoides: comparison with patients treated by total-skin electron-beam radiation therapyE C Vonderheid, E J Van Scott, P E Wallner, et al.
Radiology|February 11, 1998
Changes in high-dose-rate tandem and ovoid applicator positions during treatment in an unfixed brachytherapy systemH T Pham, Y Chen, E Rouby, et al.
Cancer Journal (Sudbury, Mass.)|August 3, 2004
Treatment margins predict biochemical outcomes after prostate brachytherapySeungtaek Choi, Kent E Wallner, Gregory S Merrick, et al.
International Journal of Radiation Oncology, Biology, Physics|June 1, 1989
Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytomaK E Wallner, J H Galicich, G Krol, et al.
Nanotechnology|January 9, 2010
Stable enhancement of near-band-edge emission of ZnO nanowires by hydrogen incorporationA Dev, R Niepelt, J P Richters, et al.
American Journal of Clinical Oncology|December 4, 2004
Permanent interstitial brachytherapy for clinically organ-confined high-grade prostate cancer with a pretreatment PSA < 20 ng/mLGregory S Merrick, Wayne M Butler, Kent E Wallner, et al.
Brachytherapy|November 4, 2015
Is supplemental external beam radiation therapy essential to maximize brachytherapy outcomes in patients with unfavorable intermediate-risk disease?Gregory S Merrick, Kent E Wallner, Robert W Galbreath, et al.
Pageof 32